DexCom, Inc. DXCM is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last ...

G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an ...

BofA Securities maintained a Buy rating on DexCom (NASDAQ:DXCM) shares, with a steady price target of $90.00. The firm's analysts suggest the current market movement presents an appealing opportunity ...

Eversense 365, the world’s first 365-day CGM system, is the only CGM offering a year-long wear time. Market-leading, ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Second, DexCom has expanded its product offerings. Last year, it launched Stelo in the U.S., an over-the-counter CGM option that can be used by pre-diabetes patients. This initiative significantly ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Glucose monitoring without piercing the skin is a prize companies like Apple and Samsung have been aiming for. Now, Samsung ...

In March 2024, the Food and Drug Administration cleared Dexcom’s Stelo as the ... Yet, despite the conceptual benefits of using continuous glucose monitoring for optimizing exercise, there ...

Continuous glucose monitoring (CGM) devices provide real-time blood sugar readings 24 hours a day, allowing people with type 1 or type 2 diabetes to closely track blood glucose levels and trends. Most ...

Advanced tracking devices like continuous glucose monitors (CGM) are becoming extremely popular for holistic wellness. “It’s about understanding your unique biological blueprint and creating targeted ...

Why it is a great TV show to watch if you are a fan of Arrow: It is always a treat to see Green Arrow interact with other DC heroes in crossover episodes while Titans gives you that sort of treat ...